title: Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.
abstract: Reflex sympathetic dystrophy syndrome (RSDS), which probably has a multifactorial etiology, may appear after kidney transplantation. Its clinical manifestations include severe periarticular pain with inflammatory signs, especially in knees and ankles, causing functional disability. Symptoms develop during the first 3 months after transplantation and usually disappear 3 to 6 months later without sequelae. In renal transplant recipients it has previously been related to immunosuppressive treatment with cyclosporine. Therefore we had suggested that introducing tacrolimus could be a therapeutic option. We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus. All but one patient were receiving tacrolimus monotherapy, excluding other drugs that might have been involved to cause the syndrome. It is also interesting that one of our cases develop RSDS long after transplantation when immunosuppressive treatment was changed. Symptoms correlated with an increase in alkaline phosphatase and with bone scintigraphy findings. All patients recovered without sequels 3 to 6 months afterward. In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.
authors.affiliation: Hospital Clinic, Renal Transplant Unit, University of Barcelona, Villaroel 170, Barcelona 08036, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Ybarra
authors.forename: M
authors.initials: M
authors.lastname: Crespo
authors.forename: J V
authors.initials: JV
authors.lastname: Torregrosa
authors.forename: D
authors.initials: D
authors.lastname: Fuster
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
authors.forename: F
authors.initials: F
authors.lastname: Oppenheimer
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy / Q000209:etiology*; D016559:Tacrolimus / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011241:Prednisone; D016559:Tacrolimus